阿托伐他汀对急性冠脉综合征患者血浆纤维蛋白原的影响

Clinical evaluation of atorvastatin in the improvement of plasma Fib levels in patients with acute coronary syndromes

目的:研究阿托伐他汀对急性冠脉综合征(ACS)患者血浆纤维蛋白原(Fib)的影响。方法:急性冠脉综合征患者112例,随机单盲分为阿托伐他汀组56例,常规治疗组56例,另外随机选择40例正常人做对照组。采用血凝仪法测定Fib含量。结果:急性冠脉综合征患者血浆Fib水平明显升高,明显高于正常对照组(P＜0．01);阿托伐他汀组和常规治疗组两组治疗前Fib水平比较无显著性差异(P＞0．05)。阿托伐他汀组治疗后Fib水平较前明显降低,而常规治疗组治疗后Fib水平无明显变化,两组比较有显著性差异(P＜0．01)。结论:阿托伐他汀可通过降低Fib水平改善急性冠脉综合征患者血液流变学状态,从而改善心肌供血,抑制冠心病的发生发展过程。

Objectlve：To assess the effects of atorvastatin on plasma fibrinogen （Fib） levels in patients with acute coronary syndrome （ACS）. Methods： 112 patients with ACS were randomized to receive atorvastatin plus conventional treatment （ n = 56） or conventional treatment alone （n = 56）. Additional 40 healthy adults were recruited as control group. The plasma Fib levels were monitored using an automated coagulometer method. Results： Compared to the pre-treatment, the atorvastatin-added patients experienced a significant reduction of the plasma Fib levels post the treatment （P 〈 0.01 ）, and the patients with conventional treatment alone showed no significant difference of the plasma Fib levels post the treatment （P 〉 0.05）. Conclusion： Atorvastatin improves the blood supply to cardiac muscles and the prognosis of coronary heart disease by reducing plasma Fib levels.